Literature DB >> 32349887

Clinical, behavioural and neural validation of the PANSS amotivation factor.

Mariia Kaliuzhna1, Matthias Kirschner2, Fabien Carruzzo3, Matthias N Hartmann-Riemer4, Martin Bischof4, Erich Seifritz4, Philippe N Tobler5, Stefan Kaiser6.   

Abstract

Negative symptoms in schizophrenia have been suggested to map onto two distinct factors - amotivation and diminished expression. Only recently, two-factor solutions for measuring negative symptoms have been proposed for the Positive and Negative Symptom Scale (PANSS), the most commonly used scale to assess the psychopathology of patients with schizophrenia. We aimed to validate the PANSS two-factor structure on a clinical, behavioural and neural level. For this multi-level validation, we reanalysed several datasets with patients for whom both the Brief Negative Symptom Assessment Scale (BNSS) and PANSS data were collected. We used a clinical dataset (n = 120) as well as behavioural data from an effort-based decision making task (n = 31) and functional neuroimaging data from a monetary incentive delay task (n = 41). Both tasks have previously been shown to be associated with BNSS amotivation. On the clinical level, the PANSS amotivation and diminished expression were highly correlated with their BNSS counterparts. On the behavioural level, we found that the PANSS amotivation factor but not the diminished expression factor specifically associated with willingness to invest effort to obtain a reward. On the neural level, PANSS amotivation was specifically related to reduced ventral striatal activation during reward anticipation. Our data confirm that the PANSS clearly allows distinguishing amotivation from diminished expression, as it relates selectively to specific aspects of behaviour and brain function. Our results will allow a re-analysis and sharing of existing datasets that used the PANSS to further substantiate the distinction between the two factors in neuroscientific studies and clinical trials.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amotivation; BNSS; Diminished expression; Negative symptoms; PANSS; Schizophrenia

Mesh:

Year:  2020        PMID: 32349887     DOI: 10.1016/j.schres.2020.04.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  3 in total

1.  Prevalence, Influencing Factors, and Clinical Characteristics of Cognitive Impairment in Elderly Patients With Schizophrenia.

Authors:  Guojun Liu; Xiaoying Zhang; Xiaoning Huo; Wei Li
Journal:  Front Psychiatry       Date:  2022-06-06       Impact factor: 5.435

2.  Oxidative stress biomarkers in treatment-responsive and treatment-resistant schizophrenia patients.

Authors:  Patrick Buosi; Fábio Aparecido Borghi; Angélica Marta Lopes; Isabela da Silva Facincani; Rafael Fernandes-Ferreira; Camila Ive Ferreira Oliveira-Brancati; Tayanne Silva do Carmo; Dorotéia Rossi Silva Souza; Danilo Grünig Humberto da Silva; Eduardo Alves de Almeida; Gerardo Maria de Araújo Filho
Journal:  Trends Psychiatry Psychother       Date:  2021-01-01

3.  Negative Symptom Domains Are Associated With Verbal Learning in Adolescents With Early Onset Psychosis.

Authors:  Lynn Mørch-Johnsen; Runar Elle Smelror; Dimitrios Andreou; Claudia Barth; Cecilie Johannessen; Kirsten Wedervang-Resell; Laura A Wortinger; Ricardo Díaz; Gamaliel Victoria; Torill Ueland; Ole A Andreassen; Anne M Myhre; Bjørn Rishovd Rund; Rosa Elena Ulloa; Ingrid Agartz
Journal:  Front Psychiatry       Date:  2022-01-07       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.